Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as ABT-288 Low Dose
ABT-288 · 3 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| ABT-288 Dose 1 | EXPERIMENTAL | low dose of ABT-288 |
| ABT-288 Dose 2 | EXPERIMENTAL | high dose of ABT-288 |
| Sugar Pill | PLACEBO_COMPARATOR | inactive substance |
| Arm 1, Dose 1, ABT-288 | EXPERIMENTAL | Low Dose |
| Arm 2, Dose 2, ABT-288 | EXPERIMENTAL | High dose |
| donepezil | ACTIVE_COMPARATOR | - |
| 1 | EXPERIMENTAL | ABT-288 vs placebo capsules administered orally once daily for 14 days |
| 2 | EXPERIMENTAL | ABT-288 vs placebo capsules administered orally once daily for 14 days |
| 3 | EXPERIMENTAL | ABT-288 vs placebo capsules administered orally once daily for 14 days |
| 4 | EXPERIMENTAL | ABT288 vs placebo administered orally once daily for 14 days |
| 5 | EXPERIMENTAL | ABT-288 vs placebo administered orally once daily for 14 days |
| 6 | EXPERIMENTAL | ABT-288 vs placebo administered orally once daily for 14 days |
| 7 | EXPERIMENTAL | ABT-288 vs placebo administered orally once daily for 14 days |
| 8 | EXPERIMENTAL | ABT-288 vs placebo administered orally once daily for 14 days |
| 9 | EXPERIMENTAL | ABT-288 vs placebo administered orally once daily for 14 days |
| Name | Type | Description |
|---|---|---|
| ABT-288 Low Dose | DRUG | - |
| Placebo | DRUG | inactive substance |
| ABT-288 High Dose | DRUG | - |
| ABT-288 | DRUG | Subjects will take 4 capsules once daily for 12 weeks. |
| donepezil | DRUG | Subjects will take 4 capsules once daily for 12 weeks. |
Inclusion Criteria: * Has current DSM-IV-TR diagnosis of schizophrenia confirmed by the Mini-International Neuropsychiatric Interview. * Is clinically stable while receiving antipsychotic therapy with one or two atypical antipsychotic medications: lack of hospitalizations from 4 months of Initial S...
Top 20 of 30 competitors
ABT-288 is an investigational small molecule developed by AbbVie Inc. (ticker ABBV) for neurological conditions. It was studied in Phase 2 clinical trials for Alzheimer's disease and for cognitive deficits in schizophrenia, as well as in schizophrenia itself. It is a histamine H3 receptor (HRH3) antagonist.
ABT-288 was studied for Alzheimer's disease and for cognitive deficits in schizophrenia, with additional Phase 1 work in stable schizophrenia patients. It is not an approved therapy; the trials evaluating it have been completed. Its development focused on cognitive symptoms within these neurological and psychiatric indications.
ABT-288 targets HRH3, the histamine H3 receptor, and acts as an antagonist at that receptor. Antagonism of HRH3 is the mechanism explored in its clinical program. The compound is a small molecule and was evaluated in Phase 2 studies for Alzheimer's disease and cognitive deficits in schizophrenia.
ABT-288 is developed by AbbVie Inc., which trades under the ticker ABBV. AbbVie sponsored the clinical trials evaluating the compound, including the Phase 2 studies in Alzheimer's disease and cognitive deficits in schizophrenia and the Phase 1 study in stable schizophrenia patients.
ABT-288 reached Phase 2 clinical development. It is an investigational drug and is not an approved treatment. Its Phase 2 program covered Alzheimer's disease and cognitive deficits in schizophrenia, and the trials have been completed. A Phase 1 multiple-dose study in stable schizophrenia patients was also completed.
ABT-288 has been evaluated in completed trials including NCT01077700, a Phase 2 study in cognitive deficits in schizophrenia with 214 participants in the United States, and NCT01018875, a Phase 2 study in mild-to-moderate Alzheimer's disease with 242 participants in Russia and Ukraine. NCT00888693 was a Phase 1 multiple-dose study in stable schizophrenia patients.
Yes, ABT-288 Low Dose is another name for ABT-288, the investigational HRH3 antagonist developed by AbbVie Inc. (ABBV). Both names refer to the same small molecule studied in Phase 2 trials for Alzheimer's disease and cognitive deficits in schizophrenia, so searches under either name point to the same compound.